Therapy Areas: Hereditary Disorders
23 October 2019 - The United States Food and Drug Administration (US FDA) has granted approval to United States-based Vertex Pharmaceuticals for its TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivac...
22 October 2019 - Public health agency the US Food and Drug Administration announced on Monday that it authorised the marketing of the first triple combination therapy Trikafta (elexacaftor/ivacaftor/...
18 October 2019 - Germany-based Boehringer Ingelheim has enrolled the first patient in its Phase II clinical trial BALANCE-CFTM 1 to assess a new potential treatment for cystic fibrosis, a progressive...
15 October 2019 - Biopharmaceutical company Enterprise Therapeutics Ltd reported on Tuesday the receipt of up to USD7m in funding for the development of novel chloride channel modulator ETD002 from th...
9 October 2019 - Vast Therapeutics Inc, a subsidiary of KNOW Bio LLC, announced yesterday that another of its drug candidates, BIOC11, has been named as a 'Qualified Infectious Disease Product�...
16 September 2019 - - Eligible cystic fibrosis patients living in Scotland will now have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor follo...
Related Headlines